Efficacy of intranasal Bevacizumab (Avastin) treatment in patients with hereditary hemorrhagic telangiectasia-associated epistaxis. [electronic resource]
Producer: 20110414Description: 636-8 p. digitalISSN:- 1531-4995
- Administration, Intranasal
- Adult
- Aged
- Aged, 80 and over
- Angiogenesis Inhibitors -- administration & dosage
- Antibodies, Monoclonal -- administration & dosage
- Antibodies, Monoclonal, Humanized
- Bevacizumab
- Combined Modality Therapy
- Dose-Response Relationship, Drug
- Epistaxis -- drug therapy
- Female
- Humans
- Injections
- Laser Coagulation
- Lasers, Solid-State -- therapeutic use
- Male
- Middle Aged
- Nasal Mucosa -- drug effects
- Nasal Sprays
- Recurrence
- Retrospective Studies
- Telangiectasia, Hereditary Hemorrhagic -- drug therapy
- Young Adult
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.